S.C.O.P.E. Engage logo.
S.C.O.P.E. Engage logo.
Home
About
Clinical Dilemmas
Clinical Education Videos
Selected LAIs
Clinical Trial Design Characteristics

Diego  |  AGE 45

  • Existing schizophrenia diagnosis
  • On oral AP (except clozapine)
  • LAI NOT available
  • Relapsed
Back to Scenario List

Inpatient Setting | Scenario 4

LAI Considerations

  • Discuss switching to an oral antipsychotic that has an LAI formulation
  • Accurately measuring adherence remains a significant challenge in schizophrenia. LAIs make it possible to be certain about the adherence status
    8,9,19
  • LAIs have shown robust efficacy in relapse prevention compared with oral antipsychotics
    15,22
  • LAI use may take the burden from family/caregiver monitoring of patient adherence and would help clinicians assess whether relapse occurs because of nonadherence or despite adequate medication
    19,23
Additional Considerations for LAIs

Next: Inpatient Scenario 5

Existing Schizophrenia Dx, on LAI; relapsed
References
© 2024 Teva Neuroscience, Inc.  |  
tv46-US-NP-00067 May 2023
Privacy Policy  |  Legal Notice
S.C.O.P.E. Engage logo.

By clicking the button below you agree to the following:

I am a US Health Care Professional.

I understand that S.C.O.P.E. is for educational purposes only and not to be used for the treatment or diagnosis of schizophrenia, nor is it a substitute for clinical judgment or guidelines.

Agree